Skip to main content
Premium Trial:

Request an Annual Quote

Oncomethylome to Test Methylation Biomarkers on Abbott's Samples

NEW YORK (GenomeWeb News) – The drug developer Abbott has tapped Oncomethylome to profile tumors for its cancer drug research efforts, Oncomethylome said today.
 
Oncomethylome will use its high-throughput DNA methylation platform to test its biomarkers on biological samples provided by Abbot, the company said.
 
Financial terms of the agreement were not released.

The Scan

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.